TrialRecruitment status
Recorded edit− Previous value
Not yet recruiting
+ Updated value
Recruiting
NCT06419205Phase 2Recruiting
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Study sponsor: Akebia Therapeutics
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2028-02Estimated
Enrollment · participants30Estimated
Source updated2026-08-04Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Incidence of adverse events (AEs) to evaluate the safety of ADX-097
+ Updated value
measure: Number of participants reporting treatment emergent adverse events (TEAEs)
The saved outcome text may be shortened. Check the source for full wording.
Participant count type
Recorded edit− Previous value
Actual
+ Updated value
Estimated
Enrollment · participant count
Recorded edit− Previous value
count: 0; type: ACTUAL
+ Updated value
count: 30; type: ESTIMATED
Primary completion date
Recorded edit− Previous value
2026-06
+ Updated value
2028-02
Recruitment status
Recorded edit− Previous value
Withdrawn
+ Updated value
Not yet recruiting